aTyr Pharma (LIFE) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
UPDATE: Citi Downgrades aTyr Pharma (LIFE) to Sell
May 14, 2018 4:18 PM EDT(Updated - May 15, 2018 5:30 AM EDT)
(updated to add analyst comment)
Citi downgraded aTyr Pharma (NASDAQ: LIFE) from Neutral to Sell with a price target of $1.00 (from $4.00).
Analyst Joel Beatty believes the probability of success for lead... More
aTyr Pharma (LIFE) PT Lowered to $2 at BMO Capital
May 14, 2018 12:57 PM EDTBMO Capital lowered its price target on aTyr Pharma (NASDAQ: LIFE) to $2.00 (from $4.00) while maintaining a Market Perform rating.
Analyst Matthew Luchini commented, "We remain Market Perform rated following discontinuation of the ORCA I/O program, and restructuring announcement. While the restructuring... More
